Roberto Massimo L.
- Country
- Italy
- Department
- UOC Ematologia
Research Overview
- Phase 2/3 Randomized Open‑Label Study of MK‑1045 Versus Blinatumomab in Relapsed/Refractory CD19‑Positive B‑Cell Acute Lymphoblastic Leukemia
- Efficacy and Safety Evaluation of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Patients: A Phase 1/3 Clinical Trial
- A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
Data & Insights
Has run more than one trial at 285 of 466 partner sites.
Specializations
Myeloid Disorders
The investigator specializes in treating acute myeloid leukemia (AML), including specific variants with IDH1 mutations and NPM1 mutations. Their research extends to chronic myeloid leukemia and myelofibrosis, particularly focusing on novel therapeutic approaches.
- AML Treatment Innovation
- Targeted Therapies
- Myeloproliferative Disorders
Lymphoid Malignancies
The investigator focuses on various lymphoid conditions, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Their expertise includes treating chronic lymphocytic leukemia and marginal zone lymphoma.
- B-Cell Lymphomas
- Novel Antibody Therapies
- Combination Treatment Strategies
Plasma Cell Disorders
The investigator has extensive experience in treating multiple myeloma and its precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Their work encompasses both newly diagnosed and relapsed/refractory cases.
- Multiple Myeloma Therapeutics
- Early Disease Intervention
- Immunotherapy Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.